Related Experiment Video

Updated: Jul 19, 2026

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Effect of grelin on TRX expression in chronic heart failure tissue: A protocol of systematic review and meta-analysis

Zhe Chen1, Yao Feng2, Ru-Bing Zhang3

  • 1Department of Critical Medicine.

Medicine
|June 3, 2020
PubMed

Insights

This systematic review will assess how grelin impacts thioredoxin expression (TRXE) in chronic heart failure tissue (CHFT). The findings aim to provide clear evidence on grelin

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Biochemistry

Background:

  • Chronic heart failure (CHFT) is a complex condition with significant impact on patient health.
  • Thioredoxin expression (TRXE) plays a crucial role in cellular redox balance and has implications in cardiovascular diseases.
  • Grelin, a peptide hormone, has demonstrated various physiological effects, including potential roles in cardiac function.

Purpose of the Study:

  • To systematically review and synthesize evidence from randomized controlled trials (RCTs) on the effect of grelin on thioredoxin expression (TRXE) in chronic heart failure tissue (CHFT).
  • To evaluate the current literature regarding the therapeutic potential of grelin in managing CHFT through its influence on TRXE.

Main Methods:

  • Comprehensive search of multiple electronic databases (MEDLINE, EMBASE, Cochrane Library, etc.) from inception to March 1, 2020.
  • Inclusion of all randomized controlled trials (RCTs) investigating the grelin-TRXE relationship in CHFT, irrespective of language or publication status.
  • Assessment of study quality using Cochrane risk of bias tool and evidence quality appraisal via Grading of Recommendations Assessment Development and Evaluation (GRADE).

Main Results:

  • This study will summarize and analyze existing RCTs to determine the effect of grelin on TRXE in CHFT.
  • Quantitative and qualitative synthesis of data from included studies will be performed.

Conclusions:

  • The findings will provide conclusive evidence regarding the impact of grelin on TRXE in the context of CHFT.
  • This review will inform future research and potential therapeutic strategies targeting grelin for CHFT management.
Abstract

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
800
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
607
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
575
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
150
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
171